The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200

DOI: 10.1080/2162402X.2016.1263412

Keywords: Breast cancer, epithelial-to-mesenchymal transition, miR-200 and immunotherapy, PD-L1, SLUG (SNAI2), SNAI1, ZEB-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text